WallStSmart

Citius Pharmaceuticals Inc (CTXR)vsVertex Pharmaceuticals Inc (VRTX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 182183% more annual revenue ($12.95B vs $7.11M). VRTX leads profitability with a 30.7% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 58/100 (C).

CTXR

Avoid

30

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -2.81

VRTX

Buy

58

out of 100

Grade: C

Growth: 5.3Profit: 9.0Value: 6.0Quality: 7.5
Piotroski: 3/9Altman Z: 3.61
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CTXR.

VRTXUndervalued (+44.9%)

Margin of Safety

+44.9%

Fair Value

$977.14

Current Price

$537.79

$439.35 discount

UndervaluedFair: $977.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CTXR2 strengths · Avg: 9.5/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

VRTX4 strengths · Avg: 9.8/10
Profit MarginProfitability
30.7%10/10

Keeps 31 of every $100 in revenue as profit

Operating MarginProfitability
37.8%10/10

Strong operational efficiency at 37.8%

Altman Z-ScoreHealth
3.6110/10

Safe zone — low bankruptcy risk

Market CapQuality
$137.57B9/10

Large-cap with strong market position

Areas to Watch

CTXR4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.69M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

VRTX4 concerns · Avg: 3.3/10
PEG RatioValuation
2.384/10

Expensive relative to growth rate

P/E RatioValuation
34.9x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-39.0%2/10

Earnings declined 39.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : CTXR

The strongest argument for CTXR centers on Price/Book, Debt/Equity.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 30.7% and operating margin at 37.8%. Revenue growth of 11.8% demonstrates continued momentum.

Bear Case : CTXR

The primary concerns for CTXR are Revenue Growth, EPS Growth, Market Cap.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

CTXR profiles as a value stock while VRTX is a mature play — different risk/reward profiles.

CTXR carries more volatility with a beta of 1.04 — expect wider price swings.

VRTX is growing revenue faster at 11.8% — sustainability is the question.

VRTX generates stronger free cash flow (546M), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (58/100 vs 30/100), backed by strong 30.7% margins and 11.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Citius Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products. The company is headquartered in Cranford, New Jersey.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?